Improving Lives Through

Diagnostic and
Therapeutic Solutions

AXIM is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19)

Improving Lives Through

Diagnostic and
Therapeutic Solutions

AXIM’s proprietary research intends to find new ways to diagnose and treat cancer as well as other conditions through laboratory-derived cannabinoid and oncological therapeutics.

COVID-19 TESTING

AXIM Biotechnologies has developed the first rapid (10-minute) point-of-care test that measures the concentration of neutralizing antibodies to COVID-19.

CLINICAL therapeutics

AXIM’s clinical therapeutic research focuses around an enzyme called “QSOX1” where the company hopes to bring a novel oncology drug to market 

CANCER dIAGNOSTICS

AXIM is in development of various “point-of-care” diagnostic testing products designed for the early detection of cancer

The Latest On Our Research

Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). AXIM’s NeuCovix is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. Additionally, the Company is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis.

Beating the Covid-19 crisis: the role of vaccine boosters

Vaccine boosters could have a dual positive impact on the Covid-19 pandemic. They can boost the immune response against the original SARS-CoV-2 virus, as well as provide methods to overcome the emerging viral variants that could render existing vaccines ineffective....

read more